Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
19
11
2021
accepted:
29
03
2022
revised:
10
03
2022
pubmed:
21
4
2022
medline:
5
8
2022
entrez:
20
4
2022
Statut:
ppublish
Résumé
Small cell lung cancer (SCLC) is an aggressive malignancy with no established biomarkers. Schlafen 11(SLFN11), a DNA/RNA helicase that sensitises cancer cells to DNA-damaging agents, has emerged as a promising predictive biomarker for several drug classes including platinum and PARP inhibitors. Detection of SLFN11 in circulating tumour cells (CTCs) may provide a valuable alternative to tissue sampling. SLFN11 expression was evaluated in tumour samples and characterised in circulating tumour cells (CTC) longitudinally to determine its potential role as a biomarker of response. Among 196 SCLC tumours, 51% expressed SLFN11 by IHC. In addition, 20/29 extra-thoracic high-grade neuroendocrine tumours expressed SLFN11 expression. In 64 blood samples from 42 SCLC patients, 83% (53/64) of samples had detectable CTCs, and SLFN11-positive CTCs were detected in 55% (29/53). Patients actively receiving platinum treatment had the lowest number of CTCs and a lower percentage of SLFN11-positive CTCs (p = 0.014). Analysis from patients with longitudinal samples suggest a decrease in CTC number and in SLFN11 expression that correlates with clinical response. SLFN11 levels can be monitored in CTCs from SCLC patients using non-invasive liquid biopsies. The ability to detect SLFN11 in CTCs from SCLC patients adds a valuable tool for the detection and longitudinal monitoring of this promising biomarker.
Identifiants
pubmed: 35440668
doi: 10.1038/s41416-022-01811-9
pii: 10.1038/s41416-022-01811-9
pmc: PMC9346119
doi:
Substances chimiques
Biomarkers
0
Biomarkers, Tumor
0
Nuclear Proteins
0
SLFN11 protein, human
0
Platinum
49DFR088MY
DNA
9007-49-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
569-576Subventions
Organisme : NCI NIH HHS
ID : U01 CA213273
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA243698
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207295
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA070907
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009666
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Allison Stewart C, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, et al. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget. 2017;8:28575–87.
pubmed: 28212573
doi: 10.18632/oncotarget.15338
Sousa FG, Matuo R, Tang SW, Rajapakse VN, Luna A, Sander C, et al. Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity. DNA Repair (Amst). 2015;28:107–15.
doi: 10.1016/j.dnarep.2015.01.011
Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, Ballestrero A, et al. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci USA. 2012;109:15030–5.
pubmed: 22927417
pmcid: 3443151
doi: 10.1073/pnas.1205943109
Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, et al. Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol. 2018;36:2386–94.
pubmed: 29906251
pmcid: 6085179
doi: 10.1200/JCO.2018.77.7672
Byers, LA, Bentsion, D, Gans, S, Penkov, K, Son, C, Sibille, A et al. Veliparib in combination with carboplatin and etoposide in patients with treatment-naive extensive-stage small cell lung cancer: a phase 2 randomized study. Clin Cancer Res. 2021; https://doi.org/10.1158/1078-0432.CCR-20-4259 .
Zhang, B, Ramkumar, K, Cardnell, RJ, Gay, CM, Stewart, CA, Wang, WL et al. A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers. Br J Cancer. 2021; https://doi.org/10.1038/s41416-021-01476-w .
Winkler, C, King, M, Berthe, J, Ferraioli, D, Garuti, A, Grillo, F et al. SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer. JCI Insight 2021;6:e146098.
Conteduca V, Ku SY, Puca L, Slade M, Fernandez L, Hess J, et al. SLFN11 Expression in advanced prostate cancer and response to platinum-based chemotherapy. Mol Cancer Ther. 2020;19:1157–64.
pubmed: 32127465
pmcid: 7440143
doi: 10.1158/1535-7163.MCT-19-0926
Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39:346–360.e347.
pubmed: 33482121
pmcid: 8143037
doi: 10.1016/j.ccell.2020.12.014
Ireland AS, Micinski AM, Kastner DW, Guo B, Wait SJ, Spainhower KB, et al. MYC Drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate. Cancer Cell. 2020;38:60–78.e12.
pubmed: 32473656
pmcid: 7393942
doi: 10.1016/j.ccell.2020.05.001
Stewart CA, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, et al. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020;1:423–36.
pubmed: 33521652
pmcid: 7842382
doi: 10.1038/s43018-019-0020-z
Simpson KL, Stoney R, Frese KK, Simms N, Rowe W, Pearce SP, et al. A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity. Nat Cancer. 2020;1:437–51.
pubmed: 35121965
doi: 10.1038/s43018-020-0046-2
Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, et al. Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 Axis. Cancer Cell. 2017;31:286–99.
pubmed: 28196596
pmcid: 5313262
doi: 10.1016/j.ccell.2017.01.006
Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 2012;30:525–32.
pubmed: 22253462
doi: 10.1200/JCO.2010.33.3716
Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani F, et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med. 2014;20:897–903.
pubmed: 24880617
doi: 10.1038/nm.3600
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7.
pubmed: 22460905
pmcid: 3320027
doi: 10.1038/nature11003
Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: The PROPHECY Study. J Clin Oncol. 2019;37:1120–9.
pubmed: 30865549
pmcid: 6494355
doi: 10.1200/JCO.18.01731
Puca, L, Gavyert, K, Sailer, V, Conteduca, V, Dardenne, E, Sigouros, M et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med. 2019;11:eaav0891.
Scher HI, Armstrong AJ, Schonhoft JD, Gill A, Zhao JL, Barnett E, et al. Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2021;150:83–94.
pubmed: 33894633
pmcid: 8772024
doi: 10.1016/j.ejca.2021.02.042
Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol. 2016;2:1441–9.
pubmed: 27262168
pmcid: 5206761
doi: 10.1001/jamaoncol.2016.1828
Schonhoft JD, Zhao JL, Jendrisak A, Carbone EA, Barnett ES, Hullings MA, et al. Morphology-predicted large-scale transition number in circulating tumor cells identifies a chromosomal instability biomarker associated with poor outcome in castration-resistant prostate cancer. Cancer Res. 2020;80:4892–903.
pubmed: 32816908
pmcid: 8428781
doi: 10.1158/0008-5472.CAN-20-1216
Brown, LC, Halabi, S, Schonhoft, JD, Yang, Q, Luo, J, Nanus, DM et al. Circulating tumor cell chromosomal instability and neuroendocrine phenotype by immunomorphology and poor outcomes in men with mCRPC treated with abiraterone or enzalutamide. Clin Cancer Res. 2021; https://doi.org/10.1158/1078-0432.CCR-20-3471 .
Werner SL, Graf RP, Landers M, Valenta DT, Schroeder M, Greene SB, et al. Analytical validation and capabilities of the epic CTC platform: enrichment-free circulating tumour cell detection and characterization. J Circ Biomark. 2015;4:3.
pubmed: 28936239
pmcid: 5572988
doi: 10.5772/60725
Beltran H, Jendrisak A, Landers M, Mosquera JM, Kossai M, Louw J, et al. The initial detection and partial characterization of circulating tumor cells in neuroendocrine prostate cancer. Clin Cancer Res. 2016;22:1510–9.
pubmed: 26671992
doi: 10.1158/1078-0432.CCR-15-0137
Dorantes-Heredia R, Ruiz-Morales JM, Cano-Garcia F. Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors. Transl Lung Cancer Res. 2016;5:401–12.
pubmed: 27652204
pmcid: 5009079
doi: 10.21037/tlcr.2016.07.10
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol. 2015;10:1240–2.
pubmed: 26291007
doi: 10.1097/JTO.0000000000000663
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015;10:1243–60.
pubmed: 26291008
doi: 10.1097/JTO.0000000000000630
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, V., Austria. 2020; https://www.R-project.org/ .
Scher HI, Graf RP, Schreiber NA, Jayaram A, Winquist E, McLaughlin B, et al. Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer. JAMA Oncol. 2018;4:1179–86.
pubmed: 29955787
pmcid: 6139066
doi: 10.1001/jamaoncol.2018.1621
Murai J, Feng Y, Yu GK, Ru Y, Tang SW, Shen Y, et al. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget. 2016;7:76534–50.
pubmed: 27708213
pmcid: 5340226
doi: 10.18632/oncotarget.12266
Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol. 2012;25:S18–30.
pubmed: 22214967
doi: 10.1038/modpathol.2011.150
Thunnissen E, Borczuk AC, Flieder DB, Witte B, Beasley MB, Chung JH, et al. The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An International Reproducibility Study in a Demanding Set of Cases. J Thorac Oncol. 2017;12:334–46.
pubmed: 27998793
doi: 10.1016/j.jtho.2016.12.004
Tay RY, Fernandez-Gutierrez F, Foy V, Burns K, Pierce J, Morris K, et al. Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial. Ann Oncol. 2019;30:1114–20.
pubmed: 31020334
pmcid: 6637373
doi: 10.1093/annonc/mdz122
Shishido SN, Carlsson A, Nieva J, Bethel K, Hicks JB, Bazhenova L, et al. Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. J Transl Med. 2019;17:294.
pubmed: 31462312
pmcid: 6714097
doi: 10.1186/s12967-019-2035-8
Kiniwa Y, Nakamura K, Mikoshiba A, Ashida A, Akiyama Y, Morimoto A, et al. Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation. BMC Cancer. 2021;21:287.
pubmed: 33731038
pmcid: 7968258
doi: 10.1186/s12885-021-08016-y
Frese KK, Simpson KL, Dive C. Small cell lung cancer enters the era of precision medicine. Cancer Cell. 2021;39:297–9.
pubmed: 33577787
doi: 10.1016/j.ccell.2021.02.002
Qu, S, Fetsch, P, Thomas, A, Pommier, Y, Schrump, DS, Miettinen, MM et al. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers. J Thorac Oncol. 2021; https://doi.org/10.1016/j.jtho.2021.08.763 .
Winkler C, Armenia J, Jones GN, Tobalina L, Sale MJ, Petreus T, et al. SLFN11 informs on standard of care and novel treatments in a wide range of cancer models. Br J Cancer. 2021;124:951–62.
pubmed: 33339894
doi: 10.1038/s41416-020-01199-4
Mezzadra R, de Bruijn M, Jae LT, Gomez-Eerland R, Duursma A, Scheeren FA, et al. SLFN11 can sensitize tumor cells towards IFN-gamma-mediated T cell killing. PLoS ONE. 2019;14:e0212053.
pubmed: 30753225
pmcid: 6372190
doi: 10.1371/journal.pone.0212053
Mavrommatis E, Fish EN, Platanias LC. The schlafen family of proteins and their regulation by interferons. J Interferon Cytokine Res. 2013;33:206–10.
pubmed: 23570387
pmcid: 3624771
doi: 10.1089/jir.2012.0133